Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 6, 2013, Pages 679-686

  Reed, Damon ^a,b   Kudchadkar, Ragini ^b   Zager, Jonathan S ^b   Sondak, Vernon K ^b   Messina, Jane L ^c  

^a Departments of Sarcoma Oncology   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CHILD; DECISION MAKING; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MELANOCYTE; MELANOMA; MICROSCOPY; SENTINEL LYMPH NODE;

EID: 84879388184     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0087     Document Type: Article

References (68)

1. Lewis KG. Trends in pediatric melanoma mortality in the United States, 1968 through 2004. Dermatol Surg 2008;34:152-159.
2. Wong JR, Harris JK, Rodriguez-Galindo C, Johnson KJ. Incidence of childhood and adolescent melanoma in the United States: 1973- 2009. Pediatrics 2013;131:846-854.
3. Chao MM, Schwartz JL, Wechsler DS, et al. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer 2005;44:441-448. (Pubitemid 40614491)
4. Moscarella E, Zalaudek I, Cerroni L, et al. Excised melanocytic lesions in children and adolescents: a ten-year survey. Br J Dermatol 2012;167:368-373.
5. Ceballos PI, Ruiz-Maldonado R, Mihm MC Jr. Melanoma in children. N Engl J Med 1995;332:656-662.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
7. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.
8. Tom WL, Hsu JW, Eichenfield LF, Friedlander SF. Pediatric "STUMP" lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J Am Acad Dermatol 2011;64:559-572.
9. Elder DE, Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology 2004;36:428-434. (Pubitemid 39273986)
10. Ludgate MW, Fullen DR, Lee J, et al. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer 2009;115:631-641.
11. Mills OL, Marzban S, Zager JS, et al. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol 2012;39:331-336.
12. Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999;30:513-520. (Pubitemid 29218042)
13. Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol 2010;34:314-326.
14. Trozak DJ, Rowland WD, Hu F. Metastatic malignant melanoma in prepubertal children. Pediatrics 1975;55:191-204.
15. Lange JR, Palis BE, Chang DC, et al. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 2007;25:1363-1368. (Pubitemid 46706883)
16. Mills O, Messina JL. Pediatric melanoma: a review. Cancer Control 2009;16:225-233.
17. Ruiz-Maldonado R, Tamayo L, Laterza AM, Duran C. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr 1992;120:906-911.
18. Paradela S, Fonseca E, Prieto VG. Melanoma in children. Arch Pathol Lab Med 2011;135:307-316.
19. Berg P, Wennberg AM, Tuominen R, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res 2004;14:251-255. (Pubitemid 39159136)
20. Bradford PT, Goldstein AM, Tamura D, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011;48:168-176.
21. Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005;115:649-654. (Pubitemid 43373024)
22. Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma, American Academy of Dermatology. J Am Acad Dermatol 2011;65:1032- 1047.
23. Coit DG, Andtbacka R, Anker CJ, et al. Melanoma. J Natl Compr Canc Netw 2012;10:366-.
24. Wood J, Butler CC, Hood K, et al. Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J 2011;38:112-118.
25. Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol 2010;34:314-326.
26. Casper DJ, Ross KI, Messina JL, et al. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol 2010;32:650-654.
27. Kapur P, Selim MA, Roy LC, et al. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol 2005;18:197-204. (Pubitemid 40188626)
28. Vollmer RT. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol 2004;122:499-505. (Pubitemid 39281244)
29. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008;30:117-122. (Pubitemid 351441982)
30. Al Dhaybi R, Agoumi M, Gagne I, et al. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. J Am Acad Dermatol 2011;65:357-363.
31. Zedek DC, McCalmont TH. Spitz nevi, atypical spitzoid neoplasms, and spitzoid melanoma. Clin Lab Med 2011;31:311-320.
32. Zembowicz A, Yang SE, Kafanas A, Lyle SR. Correlation between histologic assessment and fluorescence in situ hybridization using MelanoSITE in evaluation of histologically ambiguous melanocytic lesions. Arch Pathol Lab Med 2012;136:1571-1579.
33. Zimmermann AK, Hirschmann A, Pfeiffer D, et al. FISH analysis for diagnostic evaluation of challenging melanocytic lesions. Histol Histopathol 2010;25:1139-1147.
34. Gerami P, Zembowicz A. Update on fluorescence in situ hybridization in melanoma: state of the art. Arch Pathol Lab Med 2011;135:830- 837.
35. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33:1146-1156.
36. Morey AL, Murali R, McCarthy SW, et al. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology 2009;41:383-387.
37. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;163:1765-1770. (Pubitemid 37310008)
38. Harvell JD, Kohler S, Zhu S, et al. High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded Spitz nevi and melanomas. Diagn Mol Pathol 2004;13:22- 25. (Pubitemid 38263879)
39. Ali L, Helm T, Cheney R, et al. Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasms. Int J Clin Exp Pathol 2010;3:593-599.
40. Vanison C, Tanna N, Murthy AS. Comparative genomic hybridization for the diagnosis of melanoma. Eur J Plast Surg 2010;33:45-48.
41. Braun RP, Gutkowicz-Krusin D, Rabinovitz H, et al. Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'? Dermatology 2012;224:51- 58.
42. Wong JY, Sondak VK. Unanswered questions about margin recommendations for primary cutaneous melanoma. J Natl Compr Canc Netw 2012;10:357-365.
43. Coit DG, Andtbacka R, Bichakjian CK, et al. Melanoma. J Natl Compr Canc Netw 2009;7:250-275.
44. Kell MR, Ridge JA, Joseph N, Sigurdson ER. PET CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur J Surg Oncol 2007;33:911-913. (Pubitemid 47279044)
45. Schmid-Wendtner MH, Paerschke G, Baumert J, et al. Value of ultrasonography compared with physical examination for the detection of locoregional metastases in patients with cutaneous melanoma. Melanoma Res 2003;13:183-188. (Pubitemid 36583982)
46. Voit CA, van Akkooi AC, Schafer-Hesterberg G, et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol 2009;27:4994-5000.
47. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012;380:499-505.
48. Han D, Zager JS, Han G, et al. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol 2012;19:3888- 3895.
49. Mills OL, Marzban S, Zager JS, et al. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol 2012;39:331-336.
50. Howman-Giles R, Shaw HM, Scolyer RA, et al. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. Ann Surg Oncol 2010;17:138-143.
51. Mu E, Lange JR, Strouse JJ. Comparison of the use and results of sentinel lymph node biopsy in children and young adults with melanoma. Cancer 2012;118:2700-2707.
52. Roaten JB, Partrick DA, Pearlman N, et al. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg 2005;40:232-235. (Pubitemid 40143564)
53. Berk DR, LaBuz E, Dadras SS, et al. Melanoma and melanocytic tumors of uncertain malignant potential in children, adolescents and young adults-the Stanford experience 1995-2008. Pediatr Dermatol 2010;27:244-254.
54. Cerrato F, Wallins JS, Webb ML, et al. Outcomes in pediatric atypical spitz tumors treated without sentinel lymph node biopsy. Pediatr Dermatol 2012;29:448-453.
55. Aldrink JH, Selim MA, Diesen DL, et al. Pediatric melanoma: a single-institution experience of 150 patients. J Pediatr Surg 2009;44:1514- 1521.
56. Hung T, Piris A, Lobo A, et al. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol 2013;44:87-94.
57. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012;30:2912-2918.
58. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010;17:3324-3329.
59. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006;13:809-816. (Pubitemid 43727365)
60. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa- 2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17. (Pubitemid 26019991)
61. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677. (Pubitemid 38435557)
62. Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol 2001;19:1430-1436. (Pubitemid 32202550)
63. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458. (Pubitemid 30415832)
64. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380. (Pubitemid 32391207)
65. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:493-501.
66. Navid F, Furman WL, Fleming M, et al. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer 2005;103:780-787. (Pubitemid 40216407)
67. Gibbs P, Moore A, Robinson W, et al. Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol 2000;22:428-432. (Pubitemid 33599750)
68. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-126. (Pubitemid 351952257)